Abstract:Introduction: EGFR-mutated NSCLC is characterized by an immunosuppressive microenvironment that confers limited clinical effectiveness to anti-PD-1 or PD-L1 antibodies. Despite the discouraging outcomes of immunotherapy, novel immune checkpoints are constantly emerging, among which the specific vulnerability for therapeutic intervention in the context of EGFR-mutated NSCLC remains unresolved. Methods: Data sets of patient- and cell line-levels were used for screening and mutual validation of association between EGFR mutation and a panel of immune checkpoint-related genes. Regulatory mechanism was elucidated through in vitro manipulation of EGFR signaling pathway and evaluated by immunoblot analysis, quantitative polymerase chain reaction, flow cytometry, immunofluorescence staining, and chromatin immunoprecipitation. In vivo investigation of different therapeutic strategies were conducted using both immunocompetent and immunodeficient mouse models. Results: Among all screened immune checkpoints, CD47 emerged as the candidate most relevant to EGFR activation. Mechanistically, EGFR mutation constitutively activated downstream ERK and AKT pathways to respectively up-regulate the transcriptional factors c-Myc and NF-κB, both of which structurally bound to the promotor region of CD47 and actively transcribed this "don't eat me" signal. Impaired macrophage phagocytosis was observed on introduction of EGFR-sensitizing mutations in NSCLC cell line models, whereas CD47 blockade restored the phagocytic capacity and augmented tumor cell killing in both in vitro and in vivo models. Remarkably, the combination of anti-CD47 antibody with EGFR tyrosine kinase inhibitor revealed an additive antitumor activity compared with monotherapy of either antitumor agent in both immunocompetent and adaptive immunity-deficient mouse models. Conclusions: EGFR-sensitizing mutation facilitates NSCLC's escape from innate immune attack through up-regulating CD47. Combination therapy incorporating CD47 blockade holds substantial promise for clinical translation in developing more effective therapeutic approaches against EGFR-mutant NSCLC.

Characterization of Cluster of Differentiationï¿½47 Expression and Its Potential As a Therapeutic Target in Esophageal Squamous Cell Cancer

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

CD47 Blockade Inhibits Tumor Progression Through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer

Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy

Role of CD47 in tumor immunity: a potential target for combination therapy

CD47 Expression in Gastric Cancer Clinical Correlates and Association with Macrophage Infiltration.

PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma

The CD47-SIRPα Axis is a Promising Target for Cancer Immunotherapies

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

CD47-mediated immune evasion in early-stage lung cancer progression

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells

Tumor CD47 Expression and a High M2/M1 Ratio of Tumor-Associated Macrophages As an Adverse Prognostic Factor in Resected Stage Ⅲa Non-Small Cell Lung Cancer.

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

Facilitating cholangiocarcinoma inhibition by targeting CD47

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Cd47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small-Cell Lung Cancer

Anti-CD47 Treatment Enhances Anti-Tumor T-cell Immunity and Improves Immunosuppressive Environment in Head and Neck Squamous Cell Carcinoma